Chimerix to Host Annual Investor Update on April 27, 2017
April 20 2017 - 8:00AM
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed
to discovering, developing and commercializing medicines that
address significant, unmet medical needs, today announced that it
will host the Company's annual investor update event on April 27,
2017, from 4:30 p.m. to 6:30 p.m. ET.
Garrett Nichols, MD, MS, Chimerix's Chief Medical Officer will
provide details and timelines on the Company's planned AdAPT trial
(Study 999) of short-course oral brincidofovir for the treatment of
adenovirus infection. In addition, Dr. Nichols will review newly
available results from the single ascending dose study of IV
brincidofovir, and plans to generate multiple-dose PK and safety
data in healthy subjects as well as patient populations. These data
are intended to inform the planned pivotal MVP-peds study for
Multi-Viral Prevention of DNA viral infections.
The event will also feature keynote presentations from Thomas
Lion, MD, PhD, Professor and Medical Director of the Children's
Cancer Research Institute (Vienna, Austria) who will address the
rapidly changing field of adenovirus infections in
immunocompromised patients. Joshua Hill, MD, Associate in the
Vaccine and Infectious Disease Division at the Fred Hutchinson
Cancer Research Center (Seattle, Washington) will share his
research on the frequency of multiple viral infections in both
adult and pediatric transplant recipients and the impact of viral
infections on survival in the first year post-transplant. Linda
Richardson, Chimerix's Chief Commercial Officer, will provide an
overview of the potential market for brincidofovir oral and IV
formulations in Europe and the US.
To access the live webcast, please visit the Investor Relations
section of Chimerix's website at http://ir.chimerix.com/events.cfm.
An archived replay of the webcast will also be available at the
same location.
About ChimerixChimerix is a biopharmaceutical
company dedicated to discovering and developing medicines that
improve outcomes for immunocompromised patients. Chimerix's
proprietary lipid conjugate technology has produced brincidofovir
(BCV, CMX001); CMX157, which was licensed to ContraVir
Pharmaceuticals; and earlier-stage compounds. Chimerix recently
announced a new clinical candidate, CMX521, for the treatment
and/or prevention of norovirus. For further information, please
visit Chimerix's website,
www.chimerix.com.
Forward-Looking StatementsThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that are subject
to risks, uncertainties and other factors, including the
possibility that there may not be a viable continued development
path for BCV, that any clinical trials we may conduct will not
demonstrate adequate efficacy and safety of BCV, that enrollment in
clinical trials we may conduct may be insufficient or slower than
we anticipate, that the FDA and other regulatory authorities may
not approve BCV or BCV-based regimens, and that marketing
approvals, if granted, may have significant limitations on their
use. As a result, BCV may never be successfully commercialized. In
addition, Chimerix may be unable to file for regulatory approval
for BCV with other regulatory authorities. These risks,
uncertainties and other factors could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. Risks are described more fully in the
Company's filings with the Securities and Exchange Commission,
including without limitation the Company's most recent Annual
Report on Form 10-K and other documents subsequently filed with or
furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this Current Report on Form
8-K speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
CONTACT:
Investor Relations:
ir@chimerix.com
or
Will O'Connor
Stern Investor Relations
Will@sternir.com
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com
413-478-2003
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024